Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Venetoclax monotherapy is effective for treating relapsed / refractory CLL, including in patients previously treated with BTK or PI3K inhibitors.
A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.
Venetoclax is an effective treatment for CLL patients with no prior exposure to BTK inhibitors, but less effective for patients who have progressed on a BTK.
Five years after completing venetoclax – obinutuzumab to treat chronic lymphocytic leukemia (CLL), over half of the treatment-naive patients remained in remission, and over 60% did not require second-line treatment, including many high-risk patients.
With a four-year follow-up, fixed-duration I + V continues to provide deep, durable remissions with clinically meaningful progression-free survival (PFS) and time off treatment, including in patients with high-risk disease features.
Atezolizumab, obinutuzumab, and venetoclax combination therapy is active in patients with untreated DLBCL-Richter’s Syndrome (RS).
In the setting of the COVID-19 pandemic, progression-free survival with first-line ibrutinib + venetoclax + obinutuzumab treatment was not superior to ibrutinib + obinutuzumab for older patients with previously untreated CLL. Follow-up remains ongoing, and many patients in the ibrutinib + venetoclax + obinutuzumab arm achieved undetectable measurable residual disease.
One click to our most popular content.
